The Pharmacological Potential of Adenosine A(2A) Receptor Antagonists for Treating Parkinson’s Disease

The adenosine A(2A) receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson’s disease (PD). The selective A(2A) receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Akihisa, Chen, Jiang-Fan, Uchida, Shinichi, Durlach, Cecile, King, Shelby M., Jenner, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000505/
https://www.ncbi.nlm.nih.gov/pubmed/35408767
http://dx.doi.org/10.3390/molecules27072366
Descripción
Sumario:The adenosine A(2A) receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson’s disease (PD). The selective A(2A) receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to levodopa/decarboxylase inhibitors in adults with PD experiencing OFF episodes or a wearing-off phenomenon; however, the full potential of this drug class remains to be explored. In this article, we review the pharmacology of adenosine A(2A) receptor antagonists from the perspective of the treatment of both motor and non-motor symptoms of PD and their potential for disease modification.

Ejemplares similares